



Mediskt  
programarbete

# Referensförteckning

*Regionalt vårdprogram*

**Schizofreni och andra  
psykossjukdomar**

Stockholms läns landsting

2008





## **Innehåll**

Innehåll .....	2
1. Inledning .....	3
2. Sammanfattning .....	3
3. Kartläggning .....	4
4. Risk och skyddsfaktorer – Breda hälsofrämjande åtgärder.....	6
5. Risktillstånd vid psykos .....	9
6. Anamnes, diagnostik, utredning och uppföljning .....	10
7. Nyinsjuknade i psykos – Behandling och omhändertagande.....	13
8. Vård av långtidssjuka psykotiska patienter.....	16
9. Stigmatisering .....	22
10. Brukarinflytande .....	22
11. Samverkan.....	22

## **1. Inledning**

1. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry*. 2002 Oct;59(10):921-8.
2. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. *Arch Gen Psychiatry*. 2004 Feb;61(2):143-50.
3. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. *Psychiatr Serv*. 2000 Feb;51(2):216-22.
4. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. *Arch Gen Psychiatry*. 2005 Mar;62(3):247-53.
5. Laessle R, Pfister H, Wittchen HU. Risk of rehospitalization of psychotic patients. A 6-year follow-up investigation using the survival approach. *Psychopathology*. 1987;20(1):48-60.
6. Caldwell CB, Gottesman, II. Schizophrenia--a high-risk factor for suicide: clues to risk reduction. *Suicide & life-threatening behavior*. 1992 Winter;22(4):479-93.
7. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *Br J Psychiatry*. 2001 Jun;178:506-17.

## **2. Sammanfattning**

1. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. *Arch Gen Psychiatry*. 2005 Mar;62(3):247-53.
2. McCabe R, Heath C, Burns T, Priebe S. Engagement of patients with psychosis in the consultation: conversation analytic study. *Bmj*. 2002 Nov 16;325(7373):1148-51.

3. Priebe S, McCabe R. The therapeutic relationship in psychiatric settings. *Acta Psychiatr Scand Suppl.* 2006(429):69-72.
4. Priebe S, McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, et al. Structured patient-clinician communication and 1-year outcome in community mental healthcare: cluster randomised controlled trial. *Br J Psychiatry.* 2007 Nov;191:420-6.
5. Flyckt L, Taube A, Edman G, Jedenius E, Bjerkenstedt L. Clinical characteristics and insight in a group of severely ill schizophrenics. *Nord J Psychiatry.* 1999;53:377-82.
6. David A, van Os J, Jones P, Fahy T, Harvey I. Insight and course of psychotic illness: cross-sectional and longitudinal associations. *Br J Psychiatry.* 1995;167:621-8.
7. Drake RJ, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. *J Clin Psychiatry.* 2007 Jan;68(1):81-6.
8. Cullberg J, Mattsson M, Levander S, Holmqvist R, Tomsmark L, Elingfors C, et al. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish "Parachute Project" and two comparison groups. *Acta Psychiatr Scand.* 2006 Oct;114(4):274-81.
9. Ambition och ansvar. Nationell strategi för utveckling av samhällets insatser till personer med psykiska sjukdomar och funktionshinder. Slutbetänkande av nationell psykiatrisamordning, SOU 2006:100.

### **3. Kartläggning**

1. Harding CM, Zubin J, Strauss JS. Chronicity in schizophrenia revisited. *Br J Psychiatry Suppl.* 1992 ;18: 27-37.
2. Strömberg E. Changes in incidence of schizophrenia? *Br J Psychiatry* 1987; 150: 1-7.
3. McGrath J, Saha S, Welham J, Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Medicine* 2004;2:1-22 .

4. Mortensen, P., Pedersen, C., Westergaard, T., Wohlfahrt, J., Ewald, H., Mors, O., Andersen, P. and Melbye, M. (1999). Effects of family history and place and season of birth on the risk of schizophrenia. *New England Journal of Medicine* 340, 603- 608.
5. Wicks S, Hjern A, Gunnell D, Lewis G, Dalman C. Social adversity in childhood and the risk of developing psychosis- a national cohort study. *Am J Psychiatry* 2005; 162: 1652-1657.
6. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry*. 2004 Feb;184:110-7. Review.
7. Cantor-Graae, E, Selten JP. (2005) Schizophrenia and migration: a meta-analysis and review. *American Journal of Psychiatry*, 162:12-24.
8. Hjern A., Wicks S., Dalman C. Social adversity contributes to high morbidity in psychoses in immigrants- a national cohort study in two generations of Swedish residents. *Psychological Medicine* 2004; 34: 1025-1033.
9. Jablensky A. The epidemiological horizon in Schizophrenia. Second ed. Hirsch & Weinberger.
10. Andlin-Sobacki P, Jonsson B, Wittchen HU, et al. Costs of disorders of the brain in Europe. *Eur J Neurol* 2005; 12: 1-27.
11. Almond S, Knapp M, Francois C, Tuomi M, Brugha T. Relapse in schizophrenia. costs, clinical outcomes and quality of life. *Br J Psychiatry* 2004; 184:346-351.
12. Aleman A, Kahn R, Selten JP. Sex difference in the risk of schizophrenia. Evidence from meta-analysis. *Arch Gen Psychiatry* 2003; 60: 565-571.
13. Häfner H. Gender differences in schizophrenia. *Psychoneuroendocrinology* 2003; 28: 17-54.
14. Leung A & Chue P. Sex differences in schizophrenia, a review of the literature. *Acta Psychiatr Scand* 2000; 101: 3-38.
15. Möller I, Ponco de Leon A, Burström B. Variationer i vårdkostnader bland slutenvårdade med psykosdiagnos i Stockholms län 1997-2002. Rapport 2006:9. Centrum för folkhälsa. Epidemiologiska enheten.
16. Fazel S, Grann M. The population impact of severe mental illness on violent crime. *Am J Psychiatry* 2006; 163: 1397-1403.

17. Shaw J, Appleby L, Amos T. Mental disorder and clinical care in people convicted of homicide: national clinical survey. *BMJ* 1999; 318: 1240-1244.
18. Fazel S, Grann M. Psychiatric morbidity among homicide offenders: a Swedish population study. *Am J Psychiatry* 2004; 161: 2129-2131.
19. Barnett J, Werners U, Secher S et al. Substance use in a population-based clinic sample of people with first-episode psychosis. *Br J Psychiatry* 2007; 190: 515-520.

## **4. Risk och skyddsfaktorer – Breda hälsofrämjande åtgärder**

1. Cardno AG, Marshall EJ, Coid B et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. *Arch Gen Psychiatry* 1999; 56: 162-168.
2. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry*. 2004 Feb;184:110-7. Review.
3. Skerfving A. Barn till psykiskt störda föräldrar- Sårbarhet, risker och skyddande faktorer. En kunskapsammansättning. Rapport 1996:12. FoU-enheten/psykiatri Västre Stockholms sjukvårdsområde, 1996.
4. Lichtenstein P, Björk C, Hultman C, Scolnick E, Sklar P, Sullivan P. Recurrence risks for schizophrenia in a Swedish national cohort. *Psychological medicine*. 2006;
5. Tienari P, Wynne LC, Sorri A, Lahti I, Laksy K, Moring J, Naarala M, Nieminen P, Wahlberg KE. Genotype-environment interaction in schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees. *Br J Psychiatry* 2004; 184: 216-222.
6. Cannon M, Jones P, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. *Am J Psychiatry*. 2002 Jul;159(7):1080-92.
7. Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M: Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. *Arch Gen Psychiatry* 1999; 56(3):234-40.

8. Susser E, Neugebauer R, Hoek HW, Brown AS, Lin S, Labovitz D, Gorman JM: Schizophrenia after prenatal famine. Further evidence . Arch Gen Psychiatry 1996; 53:25-31.
9. St Clair D, Xu M, Wang P, Yu Y, Fang Y, Zhang F et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine 1959-61. JAMA 2005;294:557-562.
10. Brown A, Bottiglieri T, Schaefer C, Quesenberry C, Liu L, Bresnahan M, Susser E. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007; 64: 31-39.
11. Huttunen, M.O., Niskanen, P. (1978). Prenatal loss of father and psychiatric disorders. Archives of General Psychiatry 35, 429-431.
12. Spauwen J, Krabbendam L, Lieb R, Wittchen HU, van Os J. Early maternal stress and health behaviours and offspring expression of psychosis in adolescence. Acta Psychiatr Scand 2004; 110: 356-364.
13. Brown, A.S., et al., Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry, 2005. 162(4): p. 767-73.
14. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Torrey EF, Yolken RH: Toxoplasma gondii as a Risk Factor for Early-Onset Schizophrenia: Analysis of Filter Paper Blood Samples Obtained at Birth. Biol Psychiatry 2006
15. Brown, A.S., et al., Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry, 2004. 61(8): p. 774-80.
16. Dalman C., Allebeck P. Paternal age and schizophrenia: Further support for an association. Am J Psychiatry 2002; 159: 1591-1592.
17. Zammit S., Allebeck P., Dalman C., Lundberg I., Hemmingson T., Owen M., Lewis G. Paternal age and risk of schizophrenia. Br J Psychiatry 2003; 183: 404-408.
18. Wicks S, Hjern A, Gunnell D, Lewis G, Dalman C. Social adversity in childhood and the risk of developing psychosis- a national cohort study. Am J Psychiatry 2005; 162: 1652-1657.
19. Cantor-Graae, E, Seltén JP. (2005) Schizophrenia and migration: a meta-analysis and review. American Journal of Psychiatry, 162:12-24.
20. Hjern A., Wicks S., Dalman C. Social adversity contributes to high morbidity in psychoses in immigrants- a national cohort study in two



- generations of Swedish residents. *Psychological Medicine* 2004; 34: 1025-1033.
21. Read J, van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. *Acta Psychiatr Scand* 2005; 112: 330-350.
  22. Mortensen, P., Pedersen, C., Westergaard, T., Wohlfahrt, J., Ewald, H., Mors, O., Andersen, P. and Melbye, M. (1999). Effects of family history and place and season of birth on the risk of schizophrenia. *New England Journal of Medicine* 340, 603- 608.
  23. Pedersen BC, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. *Arch Gen Psychiatry* 2001; 58: 1039-1046.
  24. Zammit, S, Allebeck, P, Andreasson, S, Lundberg, I and Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. *British Medical Journal* 325, 1199.
  25. Verdoux H, Tournier M, Cougnard A. Impact of substance use on the onset and course of early psychosis. *Schizophrenia Research* 2005; 79: 69-75.
  26. Reichenber A, Gross R, Weiser M, Bresnahan M, et al. Advancing paternal age and autism. *Arch Gen Psychiatry* 2006; 63: 1026-1032.
  27. Hultman CM, Torrång A, Tuvblad C, Cnattingius S, Larsson JO, Lichtenstein P. Birth weight and attention-deficit/hyperactivity symptoms in childhood and early adolescence: a prospective Swedish twin study. *J Am Acad Child Adolesc Psychiatry*. 2007 Mar;46(3):370-7.
  28. Hultman CM, Sparén P, Cnattingius S. Perinatal risk factors for infantile autism. *Epidemiology*. 2002 Jul;13(4):417-23.
  29. Cnattingius S, Hultman CM, Dahl M, Sparén P, Very preterm birth, birth trauma, and the risk of anorexia nervosa among girls. *Arch Gen Psychiatry*. 1999 Jul;56(7):634-8.
  30. Caspi A, Moffitt T, Cannon M, Mc Clay J et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by functional polymorphism in the Catechol-O-Methyltransferase gene: Longitudinal evidence of a gene X environment interaction. *Biol Psychiatr* 2005; 57: 1117-1127.

## **5. Risktillstånd vid psykos**

1. Häfner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. *Eur Arch Psychiatry Clin Neurosci.* 1999;249 Suppl 4:14-26.
2. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull.* 1996;22(2):353-70. Review.
3. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry.* 2002 Oct; 59 (10):921-8.
4. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. *Br J Psychiatry.* 2004 Oct;185:291-7.
5. Falk Hogstedt M. Tidig upptäckt av unga personer med risk för psykos. Ett förebyggande samverkansprojekt. Rapport 2004, Stockholms Läns Landsting.

## 6. Anamnes, diagnostik, utredning och uppföljning

1. Flyckt L, Mattsson M, Edman G, Carlsson R, Cullberg J. Predicting 5-year outcome in first-episode psychosis - a prognostic rating scale. *J Clin Psychiatry*. 2005;in press.
2. Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. *Soc Psychiatry Psychiatr Epidemiol*. 2001 Jul;36(7):332-7.
3. Jorgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: a 1-year follow-up study. *Acta Psychiatr Scand*. 1997 Aug;96(2):150-4.
4. Schwartz JE, Fennig S, Tanenberg-Karant M, Carlson G, Craig T, Galambos N, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. *Arch Gen Psychiatry*. 2000 Jun;57(6):593-600.
5. Smolik P. [The new international psychiatric classification system, ICD-10. II. New classification systems in psychiatry]. *Casopis lekaru ceskych*. 1994 Oct 10;133(19):592-5.
6. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Fourth Edition. Washington, DC: American Psychiatric Press 1994.
7. Jager M, Bottlender R, Strauss A, Moller HJ. Classification of functional psychoses and its implication for prognosis: comparison between ICD-10 and DSM-IV. *Psychopathology*. 2004 May-Jun;37(3):110-7.
8. Kay S, Fiszbein A, Opler L. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13:261-76.
9. Miller IW, Norman WH, Bishop SB, Dow MG. The Modified Scale for Suicidal Ideation: reliability and validity. *J Consult Clin Psychol*. 1986 Oct;54(5):724-5.
10. Beck RW, Morris JB, Beck AT. Cross-validation of the Suicidal Intent Scale. *Psychol Rep*. 1974 Apr;34(2):445-6.

11. Andreasen NC. Standardized remission criteria in schizophrenia. *Acta Psychiatr Scand.* 2006 Feb;113(2):81.
12. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. *Addiction (Abingdon, England).* 1993 Jun;88(6):791-804.
13. Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. *European addiction research.* 2005;11(1):22-31.
14. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl.* 1987;334:1-100.
15. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). *Br J Psychiatry.* 1995 May;166(5):654-9.
16. Hansson L, Bjorkman T, Svensson B. The assessment of needs in psychiatric patients. Interrater reliability of the Swedish version of the Camberwell Assessment of Needs instrument and results from a cross-sectional study. *Acta Psychiatr Scand.* 1995 Oct;92(4):285-93.
17. Priebe S, Gruyters T. The role of the helping alliance in psychiatric community care. A prospective study. *J Nerv Ment Dis.* 1993 Sep;181(9):552-7
18. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, GormanJM: Assessment of insight in psychosis. *Am J Psychiatry* 1993;150:873–879
19. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. *Psychol Med.* 2005 Feb;35(2):245-56.
20. Moritz S, Meier B, Kloss M, Jacobsen D, Wein C, Fricke S, et al. Dimensional structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). *Psychiatry Res.* 2002 Mar 15;109(2):193-9.
21. Muller MJ, Marx-Dannigkeit P, Schlosser R, Wetzel H, Addington D, Benkert O. The Calgary Depression Rating Scale for Schizophrenia:

- development and interrater reliability of a German version (CDSS-G). *J Psychiatr Res.* 1999 Sep-Oct;33(5):433-43.
22. Montgomery SA, Smeyatsky N, de Ruyter M, Montgomery DB. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. *Acta Psychiatr Scand Suppl.* 1985;320:38-42.
  23. Runeson BS. Suicide after parasuicide. *Bmj.* 2002 Nov 16;325(7373):1125-6.
  24. Osby U, Correia N, Brandt L, Ekblom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. *Schizophr Res.* 2000 Sep 29;45(1-2):21-8.
  25. Grann M, Pettersson A. [Risk assessment in psychiatry--can violence in society be predicted? A systematic literature review from SBU]. *Lakartidningen.* 2007 May 14-29;104(20-21):1588-9.
  26. Kaplan E, Fein D, Morris R, Delis D. WAIS-R as a neuropsychological instrument. San Antonio, TX: The Psychological Corporation 1991.
  27. Gambini O, Macciardi F, Abbruzzese M, Scarone S. Influence of education on WCST performances in schizophrenic patients. *The International journal of neuroscience.* 1992 Nov-Dec;67(1-4):105-9.
  28. Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. *J Int Neuropsychol Soc.* 2004 Mar;10(2):301-3.
  29. Cornell DG, Roberts M, Oram G. The Ray-Osterrieth Complex Figure Test as a neuropsychological measure in criminal offenders. *Arch Clin Neuropsychol.* 1997;12(1):47-56.
  30. Forbes GB. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. *J Clin Psychol.* 1998 Jun;54(4):461-76.
  31. Homack S, Riccio CA. Conners' Continuous Performance Test (2nd ed.; CCPT-II). *Journal of attention disorders.* 2006 Feb;9(3):556-8.
  32. Bouwens SF, van Heugten CM, Aalten P, Wolfs CA, Baarends EM, van Menxel DA, et al. Relationship between measures of dementia severity and observation of daily life functioning as measured with the Assessment of Motor and Process Skills (AMPS). *Dementia and geriatric cognitive disorders.* 2008;25(1):81-7.

33. Haglund L, Henriksson C. Testing a Swedish version of OCAIRS on two different patient groups. *Scandinavian journal of caring sciences*. 1994;8(4):223-30.
34. Linddahl I, Norrby E, Bellner AL. Construct validity of the instrument DOA: a dialogue about ability related to work. *Work (Reading, Mass)*. 2003;20(3):215-24.
35. Biernacki SD. Reliability of the worker role interview. *Am J Occup Ther*. 1993 Sep;47(9):797-803.
36. Kielhofner G, Lai JS, Olson L, Haglund L, Ekbadh E, Hedlund M. Psychometric properties of the work environment impact scale: a cross-cultural study. *Work (Reading, Mass)*. 1999;12(1):71-7.
37. Towle D, Wilsher CR. The Rivermead Behavioural Memory Test: remembering a short route. *The British journal of clinical psychology / the British Psychological Society*. 1989 Sep;28 ( Pt 3):287-8.

## **7. Nyinsjuknade i psykos – Behandling och omhändertagande**

1. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry*. 2002 Oct;59(10):921-8.
2. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. *Schizophr Bull*. 1996;22(2):241-56.
3. Jorgensen P, Nordentoft M, Abel MB, Gouliaev G, Jeppesen P, Kassov P. Early detection and assertive community treatment of young psychotics: the Opus Study Rationale and design of the trial. *Soc Psychiatry Psychiatr Epidemiol*. 2000 Jul;35(7):283-7.
4. Group IEPAW. International clinical practice guidelines for early psychosis. *Br J Psychiatry Suppl*. 2005 Aug;48:s120-4.
5. Cullberg J, Levander S, Holmqvist R, Mattsson M, Wieselgren IM. One-year outcome in first episode psychosis patients in the Swedish Parachute project. *Acta Psychiatr Scand*. 2002 Oct;106(4):276-85.

6. Larsen TK, Friis S, Haahr U, Johannessen JO, Melle I, Opjordsmoen S, et al. Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. *Br J Psychiatry*. 2004 Aug;185:108-15.
7. Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Melle I, et al. Early detection and intervention in first-episode schizophrenia: a critical review. *Acta Psychiatr Scand*. 2001 May;103(5):323-34.
8. Malla AK, Norman RM, Joober R. First-episode psychosis, early intervention, and outcome: what have we learned? *Can J Psychiatry*. 2005 Dec;50(14):881-91.
9. Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. *Schizophr Res*. 2002 Apr 1;54(3):231-42.
10. Malla AK, Norman RM, Manchanda R, McLean TS, Harricharan R, Cortese L, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. *Psychiatr Serv*. 2002 Apr;53(4):458-63.
11. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull*. 1996;22(2):353-70.
12. Simon AE, Ferrero FP, Merlo MC. Prodromes of first-episode psychosis: how can we challenge nonspecificity? *Compr Psychiatry*. 2001 Sep-Oct;42(5):382-92.
13. Falk-Hogstedt M. Tidig upptäckt av unga personer med risk för psykos. Ett förebyggande samverkansprojekt. Stockholm: Stockholms läns landsting; 2004.
14. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? *Biol Psychiatry*. 1999 Oct 1;46(7):899-907.
15. Melle I, Haahr U, Friis S, Hustoft K, Johannessen JO, Larsen TK, et al. Reducing the duration of untreated first-episode psychosis -- effects on baseline social functioning and quality of life. *Acta Psychiatr Scand*. 2005 Dec;112(6):469-73.
16. Hjern A, Wicks S, Dalman C. Social adversity contributes to high morbidity in psychoses in immigrants--a national cohort study in two

- generations of Swedish residents. *Psychol Med.* 2004 Aug;34(6):1025-33.
17. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. *Arch Gen Psychiatry.* 1986 Jul;43(7):633-42.
  18. Pekkala E, Merinder L. Psychoeducation for schizophrenia. *Cochrane Database Syst Rev.* 2002(2):CD002831.
  19. Wade D, Harrigan S, Harris MG, Edwards J, McGorry PD. Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. *Aust N Z J Psychiatry.* 2006 May;40(5):429-36.
  20. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. *Schizophr Res.* 2005 Nov 1;79(1):85-93.
  21. Berglund N, Vahlne JO, Edman A. Family intervention in schizophrenia--impact on family burden and attitude. *Soc Psychiatry Psychiatr Epidemiol.* 2003 Mar;38(3):116-21.
  22. Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. *Bmj.* 2005 Sep 17;331(7517):602.
  23. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. *Schizophr Res.* 2001 Aug 1;51(1):55-61.
  24. Holmes-Eber P, Riger S. Hospitalization and the composition of mental patients' social networks. *Schizophr Bull.* 1990;16(1):157-64.
  25. Aberg-Wistedt A, Cressell T, Lidberg Y, Liljenberg B, Osby U. Two-year outcome of team-based intensive case management for patients with schizophrenia. *Psychiatr Serv.* 1995 Dec;46(12):1263-6.



## 8. Vård av långtidssjuka psykotiska patienter

1. van den Berg B, Spauwen P. Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. *Health economics*. 2006 May;15(5):447-60.
2. Meyer JM. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. *J Clin Psychiatry*. 2007;68 Suppl 1:28-33.
3. Andreasen NC. Standardized remission criteria in schizophrenia. *Acta Psychiatr Scand*. 2006 Feb;113(2):81.
4. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. *Psychopharmacology*. 2004 Aug;175(1):1-6.
5. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry*. 2003 Jul;160(7):1209-22.
6. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. *Arch Gen Psychiatry*. 1995 Mar;52(3):173-88.
7. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. *Br J Psychiatry*. 1986 Feb;148:120-7.
8. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. *Am J Psychiatry*. 2001 Nov;158(11):1835-42.
9. Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. *Am J Psychiatry*. 1986 Sep;143(9):1155-8.

10. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. *Arch Gen Psychiatry*. 1982 Jan;39(1):70-3.
11. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. *CNS Drugs*. 2002;16(7):473-84.
12. Kampman O, Laippala P, Vaananen J, Koivisto E, Kiviniemi P, Kilku N, et al. Indicators of medication compliance in first-episode psychosis. *Psychiatry Res*. 2002 May 15;110(1):39-48.
13. Perkins DO. Predictors of noncompliance in patients with schizophrenia. *J Clin Psychiatry*. 2002 Dec;63(12):1121-8.
14. Weiss KA, Smith TE, Hull JW, Piper AC, Huppert JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. *Schizophr Bull*. 2002;28(2):341-9.
15. Corriss DJ, Smith TE, Hull JW, Lim RW, Pratt SI, Romanelli S. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. *Psychiatry Res*. 1999 Dec 27;89(3):269-74.
16. Flyckt L, Taube A, Edman G, Jedenius E, Bjerkenstedt L. Clinical characteristics and insight in a group of severely ill schizophrenics. *Nord J Psychiatry*. 1999;53:377-82.
17. Priebe S, Gruyters T. The role of the helping alliance in psychiatric community care. A prospective study. *J Nerv Ment Dis*. 1993 Sep;181(9):552-7.
18. Davidson L, Chinman M, Sells D, Rowe M. Peer support among adults with serious mental illness: a report from the field. *Schizophr Bull*. 2006 Jul;32(3):443-50.
19. Gartner A. Self-help and mental health. *Social policy*. 1976 Sep-Oct;7(2):28-40.
20. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. *Arch Gen Psychiatry*. 1991 Aug;48(8):739-45.
21. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. *Clinical pharmacokinetics*. 2007;46(5):359-88.

22. Schooler NR, Keith SJ, Severe JB, Matthews SM. Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. *The Psychiatric quarterly*. 1995 Winter;66(4):279-92.
23. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. *Arch Gen Psychiatry*. 1997 May;54(5):453-63.
24. Herz MI, Lamberti JS, Mintz J, Scott R, O'Dell SP, McCartan L, et al. A program for relapse prevention in schizophrenia: a controlled study. *Arch Gen Psychiatry*. 2000 Mar;57(3):277-83.
25. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. *Psychiatr Serv*. 2000 Feb;51(2):216-22.
26. Berman I, Sapers BL, Chang HH, Losonczy MF, Schmiedler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. *J Clin Psychopharmacol*. 1995 Jun;15(3):206-10.
27. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. *Am J Psychiatry*. 1999 Aug;156(8):1138-48.
28. Reznik I, Sirota P. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. *Clinical neuropharmacology*. 2000 May-Jun;23(3):157-60.
29. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2001(4):CD000209.
30. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. *Am J Psychiatry*. 1993 Sep;150(9):1405-7.
31. Stiebel VG. Maintenance electroconvulsive therapy for chronic mentally ill patients: a case series. *Psychiatr Serv*. 1995 Mar;46(3):265-8.
32. Swoboda E, Conca A, König P, Waanders R, Hansen M. Maintenance electroconvulsive therapy in affective and schizoaffective disorder. *Neuropsychobiology*. 2001 Jan;43(1):23-8.
33. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. Maintenance treatment of schizophrenia with risperido-

- ne or haloperidol: 2-year outcomes. *Am J Psychiatry*. 2003 Aug;160(8):1405-12.
34. Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. *Schizophr Bull*. 1999;25(4):709-19.
  35. Wikner C. *Novel Pharmacological Treatment Alternatives for Schizophrenia*. Stockholm; 2007.
  36. Lindefors N. *Läkemedelsboken*. Stockholm 2007:53.
  37. Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry*. 2003 Jan;60(1):82-91.
  38. Scott JE, Dixon LB. Assertive community treatment and case management for schizophrenia. *Schizophr Bull*. 1995;21(4):657-68.
  39. McFarlane WR, Stastny P, Deakins S. Family-aided assertive community treatment: a comprehensive rehabilitation and intensive case management approach for persons with schizophrenic disorders. *New directions for mental health services*. 1992 Spring(53):43-54.
  40. Lehman AF, Dixon LB, Kernan E, DeForge BR, Postrado LT. A randomized trial of assertive community treatment for homeless persons with severe mental illness. *Arch Gen Psychiatry*. 1997 Nov;54(11):1038-43.
  41. Pekkala E, Merinder L. Psychoeducation for schizophrenia. *Cochrane Database Syst Rev*. 2002(2):CD002831.
  42. Magliano L, Fiorillo A, Malangone C, De Rosa C, Maj M. Patient functioning and family burden in a controlled, real-world trial of family psychoeducation for schizophrenia. *Psychiatr Serv*. 2006 Dec;57(12):1784-91.
  43. Rummel-Kluge C, Pitschel-Walz G, Bauml J, Kissling W. Psychoeducation in schizophrenia--results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. *Schizophr Bull*. 2006 Oct;32(4):765-75.
  44. Asen E. Outcome research in family therapy. *Advances in psychiatric treatment*. 2002(8):230-8.

45. Addington J, Gleeson J. Implementing cognitive-behavioural therapy for first-episode psychosis. *Br J Psychiatry Suppl.* 2005 Aug;48:s72-6.
46. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. *Cochrane Database Syst Rev.* 2004(4):CD000524.
47. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. *Arch Gen Psychiatry.* 1986 Jul;43(7):633-42.
48. Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, et al. Cognitive remediation therapy in schizophrenia: randomised controlled trial. *Br J Psychiatry.* 2007 May;190:421-7.
49. Bell MD, Bryson GJ, Greig TC, Fiszdon JM, Wexler BE. Neurocognitive enhancement therapy with work therapy: Productivity outcomes at 6- and 12-month follow-ups. *Journal of rehabilitation research and development.* 2005 Nov-Dec;42(6):829-38.
50. Cullberg J. *Psykoser - ett integrerat perspektiv.* 2nd ed. Stockholm: Natur och Kultur 2005.
51. Lökensgård I. *Psykiatrisk vård och specifik omvårdnad.* Lund: Studentlitteratur 1997.
52. Viderbeck S. *Psychiatric mental health nursing 2001.*
53. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. *Pharmacopsychiatry.* 2006 Sep;39(5):161-70.
54. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. *Am J Psychiatry.* 2005 Mar;162(3):441-9.
55. van Os J, Drukker M, a Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. *Am J Psychiatry.* 2006 Nov;163(11):2000-2.
56. Sheitman BB, Lee H, Strauss R, Lieberman JA. The evaluation and treatment of first-episode psychosis. *Schizophr Bull.* 1997;23(4):653-61.
57. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. *Br J Psychiatry Suppl.* 1989 Nov(7):49-58.

58. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P. Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update. *Psychopathology*. 1995;28(1):7-17.
59. Kay S, Fiszbein A, Opler L. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13:261-76.
60. Silverstein ML, Mavrolefteros G, Close D. BPRS syndrome scales during the course of an episode of psychiatric illness. *J Clin Psychol*. 1997 Aug;53(5):455-8.
61. Vaillant GE. The prediction of recovery in schizophrenia. *Int J Psychiatry*. 1966 Nov;2(6):617-27.
62. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *Br J Psychiatry*. 2001 Jun;178:506-17.
63. Shahar G, Trower P, Iqbal Z, Birchwood M, Davidson L, Chadwick P. The person in recovery from acute and severe psychosis: the role of dependency, self-criticism, and efficacy. *The American journal of orthopsychiatry*. 2004 Oct;74(4):480-8.
64. Davidson L, Strauss JS. Sense of self in recovery from severe mental illness. *The British journal of medical psychology*. 1992 Jun;65 ( Pt 2):131-45.
65. Breier A, Strauss JS. The role of social relationships in the recovery from psychotic disorders. *Am J Psychiatry*. 1984 Aug;141(8):949-55.
66. Borg M, Sells D, Topor A, Mezzina R, Marin I, Davidson L. What Makes a House a Home: The Role of Material Resources in Recovery from Severe Mental Illness. In:
67. Topor A. Managing the contradictions - Recovery from severe mental disorders. Stockholm: Dept. of Social Work; 2001.
68. Topor A. Vägar till återhämtning från svåra psykiska problem. Stockholm: Natur och Kultur 2004.

## 9. Stigmatisering

1. Heginbotham C. UK mental health policy can alter the stigma of mental illness. *Lancet*. 1998 Sep 26;352(9133):1052-3.
2. Sartorius N. Stigma: what can psychiatrists do about it? *Lancet*. 1998 Sep 26;352(9133):1058-9.
3. Erdner A, Magnusson A, Nystrom M, Lutzen K. Social and existential alienation experienced by people with long-term mental illness. *Scandinavian journal of caring sciences*. 2005 Dec;19(4):373-80.
4. Jansson L, Sonnander K, Wiesel FA. Needs assessed by psychiatric health care and social services in a defined cohort of clients with mental disabilities. *Eur Arch Psychiatry Clin Neurosci*. 2005 Feb;255(1):57-64.
5. Sorgaard KW, Sandlund M, Heikkila J, Hansson L, Vinding HR, Bjarnason O, et al. Schizophrenia and contact with health and social services: a Nordic multi-centre study. *Nord J Psychiatry*. 2003;57(4):253-61.
6. Townsend A, Wyke S, Hunt K. Self-managing and managing self: practical and moral dilemmas in accounts of living with chronic illness. *Chronic illness*. 2006 Sep;2(3):185-94.

## 10. Brukarinflytande

1. Inflytande projekt, [www.inflytandeguiden.se](http://www.inflytandeguiden.se)

## 11. Samverkan

1. Ambition och ansvar. Nationell strategi för utveckling av samhällets insatser till personer med psykiska sjukdomar och funktionshinder. Slutbetänkande av nationell psykiatrisamordning, SOU 2006:100, s 325.
2. Palmstierna et al 2000
3. Öjehagen 1999

4. Meuser 2001

## **12. Kvalitetsindikatorer**

1. Utveckling och användning av kvalitetsindikatorer i Medicinskt Program Arbete. Medicinskt programarbete. Stockholms läns landsting 2004.
2. Campbell SM, Braspenning J, Hutchinson A, Marshall M. Research methods used in developing and applying quality indicators in primary care. *Qual Saf Health Care* 2002;11(4):358-64.
3. Rapport från ett förbättringsarbete. Pilotprojekt för implementering av vårdprogram i psykiatri. Medicinskt programarbete. Stockholms läns landsting 2005.
4. Lawrence M, Olesen F et al. Indicators of quality health care. *Eur Gen Pract* 1997;3:103-8.
5. Mc Glynn EA. Selecting common measures of quality and system performance. *Medical Care* 2003;41 (suppl):I-39-I-47.
6. Geredts M, Selbmann H-K, Ollenschlaeger G. Critical appraisal of clinical performance measures in Germany. *International Journal for Quality in Health Care* 2003;15:79-85.
7. Donabedian A. The quality of care: How can it be assessed? *JAMA* 1988;260:1743-8.
8. Kvalitet i psykiatrisk vård. URL <http://www.kpvcentrum.se>

## **13 Evidensgradering**

1. Socialstyrelsen, 2004. Riktlinjer för riktlinjer version 1:1, bilaga 5, sid 2